Elicera Therapeutics AB
F:8E8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (7.9), the stock would be worth €0.18 (35% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 12.2 | €0.28 |
0%
|
| 3-Year Average | 7.9 | €0.18 |
-35%
|
| 5-Year Average | 7.9 | €0.18 |
-35%
|
| Industry Average | 7.9 | €0.18 |
-35%
|
| Country Average | 2.1 | €0.05 |
-83%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
€305.2m
|
/ |
Jan 2026
kr10.9m
|
= |
|
|
€305.2m
|
/ |
Dec 2026
kr55.6m
|
= |
|
|
€305.2m
|
/ |
Dec 2027
kr24.9m
|
= |
|
|
€305.2m
|
/ |
Dec 2028
kr63.2m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
E
|
Elicera Therapeutics AB
F:8E8
|
157.5m EUR | 12.2 | -9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
355.3B USD | 6.7 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.9B USD | 6.2 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.8B USD | 5.9 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.5B USD | 8.4 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81B USD | 4 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 10.5 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.2B AUD | 3.4 | 30.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 2.1 |
| 70th Percentile | 5.1 |
| Max | 15 188 |
Other Multiples
Elicera Therapeutics AB
Glance View
Elicera Therapeutics AB operates as clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2021-06-11. The firm is developing next-generation cell and gene therapies for immune-based treatment of cancer. The firm is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
